• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza antivirals and resistance: the next 10 years?

tetano

tetano

Editor, Senior Moderator
Expert Rev Anti Infect Ther. 2012 Nov;10(11):1221-3. doi: 10.1586/eri.12.125.
Influenza antivirals and resistance: the next 10 years?
Hurt AC, Butler J, Kelso A, Barr IG.
Source

WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria 3051, Australia and Monash University, School of Applied Sciences, Churchill, Victoria 3842, Australia. aeron.hurt@influenzacentre.org.

PMID:
23241176
[PubMed - in process]

Free full text

http://www.ncbi.nlm.nih.gov/pubmed/23241176
 
Re: Influenza antivirals and resistance: the next 10 years?

from the article . . .
Antivirals against influenza first became available in the 1960s when an adamantane compound, amantadine, was approved for the treatment and prophylaxis of influenza A viruses. Rimantadine, another adamantane drug with fewer side effects than amantadine, was approved for use in the 1990s. In the late 1990s, a new class of rationally designed influenza antivirals known as the neuraminidase (NA) inhibitors (NAIs; namely oseltamivir [Tamiflu<sup>?</sup>, Hoffmann-La Roche] and zanamivir [Relenza<sup>?</sup>, GlaxoSmithKline]) became available. Since this time oseltamivir has become the most widely used influenza antiviral drug around the world, due in part to widespread resistance to the adamantanes and lower patient acceptance of inhaled zanamivir. However, with increasing concerns about oseltamivir resistance in A(H1N1)pdm09 viruses, the case for the development of new influenza antivirals is compelling. Here, the authors highlight some novel anti-influenza compounds that are in late-phase clinical trials, and discuss the likelihood of resistance to these and the current NAI compounds emerging in the next 10 years. . . .
Click to expand...
full article at: http://www.expert-reviews.com/doi/full/10.1586/eri.12.125
<object style="position:absolute;z-index:1000" type="application/x-dgnria" id="plugin0" height="0" width="0">

</object>
 
You must log in or register to reply here.
Back
Top Bottom